Rigosertib: Difference between revisions
Niceguyedc (talk | contribs) m WPCleaner v1.33 - Repaired 1 link to disambiguation page - (You can help) - PLK / Fixed using WP:WCW (Spelling and typography) |
this data is dubiously highly and too precise to be "real" values - calculated, predicted, or theoretical values should not be included |
||
| Line 18: | Line 18: | ||
| Density = |
| Density = |
||
| MeltingPt = |
| MeltingPt = |
||
| BoilingPt = |
| BoilingPt = |
||
| Solubility = }} |
| Solubility = }} |
||
| Section3 = {{Chembox Hazards |
| Section3 = {{Chembox Hazards |
||
| MainHazards = |
| MainHazards = |
||
| FlashPt = |
| FlashPt = |
||
| Autoignition = }} |
| Autoignition = }} |
||
}} |
}} |
||
'''Rigosertib''' ('''ON-01910''' sodium salt, with '''Estybon''' as trade name) is a synthetic benzyl styryl sulfone analogue,of which (E)-ON 01910·Na is on a phase III clinical stage anti-cancer agent and its [[geometrical isomer]] (Z)-ON 01910·Na is with less cytotoxicity on cancer cells. |
'''Rigosertib''' ('''ON-01910''' sodium salt, with '''Estybon''' as trade name) is a synthetic benzyl styryl sulfone analogue,of which (E)-ON 01910·Na is on a phase III clinical stage anti-cancer agent and its [[geometrical isomer]] (Z)-ON 01910·Na is with less cytotoxicity on cancer cells. |
||
==Mechanism== |
==Mechanism== |
||
Revision as of 15:23, 21 August 2014
 | |
| Names | |
|---|---|
| IUPAC name
sodium (E)-2-((2-methoxy-5-(((2,4,6-trimethoxystyryl)sulfonyl)methyl)phenyl)amino)acetate
| |
| Identifiers | |
3D model (JSmol)
|
|
CompTox Dashboard (EPA)
|
|
| Properties | |
| C21H24NNaO8S | |
| Molar mass | 473.47g/mol |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
| |
Rigosertib (ON-01910 sodium salt, with Estybon as trade name) is a synthetic benzyl styryl sulfone analogue,of which (E)-ON 01910·Na is on a phase III clinical stage anti-cancer agent and its geometrical isomer (Z)-ON 01910·Na is with less cytotoxicity on cancer cells.
Mechanism
Rigosertib is a small molecule inhibitor, which simultaneously inhibits PI3K and PLK signaling pathways.The over-expression of these two pathways may lead occurrence and development of many kinds of tumors. [2]Thus Rigosertib performs potential antineoplastic activity in multiple tumors.
Rigosertib can convert the gene express profilings, cause mitotic cell-cycle G2 arrest of tumor cells, leading their apoptosis. And what it causes in normal cells is a reversible cell arrest at the G1 and G2 stage without apoptosis .Maybe that's why Rigosertib show little liver damage, or neurotoxicity in mouse xenograft models.
Rigosertib is an non-ATP-competitive inhibitor.It inhibits PLK1 by competing substrate- binding sites with IC50 of 9 nM.[3]
References
- ^ "physical and chemical data on chemispider website".
- ^ Nuthalapati S (Sep.2012). "Preclinical pharmacokinetic and pharmacodynamic evaluation of novel anticancer agents, ON01910.Na (Rigosertib, Estybon™) and ON013105, for brain tumor chemotherapy". Pharm Res. 29 (9). doi:10.1007/s11095-012-0780-y.
{{cite journal}}: Check date values in:|date=(help) - ^ "Rigosertib activity data in vitro and in vivo". selleckchemicals. 20 Aug 2014.